Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FOLH1 | Q04609 | 1/20 | 0.60 |
| ▸ | KDM6B | O15054 | 1/20 | 0.50 |
| ▸ | LMNA | P02545 | 1/20 | 0.48 |
| ▸ | GLA | P06280 | 1/20 | 0.48 |
| ▸ | PIN1 | Q13526 | 1/20 | 0.47 |
| ▸ | FFAR1 | O14842 | 3/20 | 0.47 |
| ▸ | FFAR4 | Q5NUL3 | 1/20 | 0.47 |
| ▸ | MEP1A | Q16819 | 1/20 | 0.47 |
| ▸ | MEP1B | Q16820 | 1/20 | 0.47 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.46 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.46 |
| ▸ | DPP4 | P27487 | 2/20 | 0.45 |
| ▸ | DPP7 | Q9UHL4 | 2/20 | 0.45 |
| ▸ | FAP | Q12884 | 1/20 | 0.45 |
| ▸ | DPP8 | Q6V1X1 | 1/20 | 0.45 |
| ▸ | DPP9 | Q86TI2 | 1/20 | 0.45 |
| ▸ | CCR2 | P41597 | 1/20 | 0.45 |
| ▸ | MMP12 | P39900 | 1/20 | 0.45 |
| ▸ | MMP13 | P45452 | 1/20 | 0.45 |
| ▸ | MAOB | P27338 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23138998 | 1.00 | FOLH1 (0.60) | FOLH1KDM6BLMNAGLAPIN1 | |
| SCHEMBL20702757 | 1.00 | FOLH1 (0.60) | FOLH1KDM6BLMNAGLAPIN1 | |
| SCHEMBL3470878 | 0.87 | FOLH1 (0.63) | FOLH1LMNAGLAPIN1FFAR1 | |
| SCHEMBL12653044 | 0.83 | FOLH1 (0.59) | FOLH1LMNAGLAPIN1FFAR1 | |
| SCHEMBL29397955 | 0.83 | FOLH1 (0.59) | FOLH1DPP4DPP7FAPDPP8 | |
| SCHEMBL29557415 | 0.83 | FOLH1 (0.59) | FOLH1DPP4DPP7FAPDPP8 | |
| SCHEMBL43811 | 0.83 | FOLH1 (0.59) | FOLH1DPP4DPP7FAPDPP8 | |
| SCHEMBL838038 | 0.83 | FOLH1 (0.59) | FOLH1DPP4DPP7FAPDPP8 | |
| SCHEMBL43812 | 0.83 | FOLH1 (0.59) | FOLH1DPP4DPP7FAPDPP8 | |
| SCHEMBL28549815 | 0.83 | FOLH1 (0.59) | FOLH1LMNAGLAPIN1FFAR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250223263-A1 | SELECTIVE INHIBITORS OF NLRP3 INFLAMMASOME | NodThera Limited (GB) | 2025-07-10 | — | — | US | disclosed |
| US-12247011-B2 | Selective inhibitors of NLRP3 inflammasome | NodThera Limited (GB) | 2025-03-11 | — | — | US | disclosed |
| CN-111356680-B | Selective inhibitors of NLRP3 inflammasome | 诺瑟拉有限公司 | 2023-11-28 | — | — | CN | disclosed |
| EP-3661921-B1 | SELECTIVE INHIBITORS OF NLRP3 INFLAMMASOME | NODTHERA LTD (GB) | 2023-10-18 | — | — | EP | disclosed |
| US-20210087147-A1 | SELECTIVE INHIBITORS OF NLRP3 INFLAMMASOME | NodThera Limited (GB) | 2021-03-25 | — | — | US | disclosed |
| US-20210087147-A1 | SELECTIVE INHIBITORS OF NLRP3 INFLAMMASOME | NodThera Limited (GB) | 2021-03-25 | — | — | US | disclosed |
| CN-111356680-A | Selective inhibitors of NLRP3inflammasome | 诺瑟拉有限公司 | 2020-06-30 | — | — | CN | disclosed |
| EP-3661921-A1 | SELECTIVE INHIBITORS OF NLRP3 INFLAMMASOME | Nodthera Limited (GB) | 2020-06-10 | — | — | EP | disclosed |
| WO-2019025467-A1 | SELECTIVE INHIBITORS OF NLRP3 INFLAMMASOME | NodThera Limited (GB) | 2019-02-07 | — | — | WO | disclosed |
| EP-0892780-B1 | M-AMIDINO PHENYL ANALOGS AS FACTOR Xa INHIBITORS | BRISTOL MYERS SQUIBB PHARMA CO (US) | 2002-11-20 | — | — | EP | disclosed |
| US-5942544-A | α-branched anilines, toluenes, and analogs thereof as factor Xa inhibitors | DUPONT PHARMACEUTICALS COMPANY (US) | 1999-08-24 | — | — | US | disclosed |
| EP-0892780-A1 | M-AMIDINO PHENYL ANALOGS AS FACTOR Xa INHIBITORS | THE DU PONT MERCK PHARMACEUTICAL COMPANY (US) | 1999-01-27 | — | — | EP | disclosed |
| WO-1997030971-A1 | M-AMIDINO PHENYL ANALOGS AS FACTOR Xa INHIBITORS | THE DU PONT MERCK PHARMACEUTICAL COMPANY (US) | 1997-08-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12247011-B2 | Selective inhibitors of NLRP3 inflammasome | NLRP3, NOD1, NLRP1 | FOLH1 2552/4885KDM6B 3715/4885LMNA 1234/4885 |
| US-20250223263-A1 | SELECTIVE INHIBITORS OF NLRP3 INFLAMMASOME | NLRP3, NOD1, NLRP1 | FOLH1 2552/4885KDM6B 3715/4885LMNA 1234/4885 |
| US-20210087147-A1 | SELECTIVE INHIBITORS OF NLRP3 INFLAMMASOME | NLRP3, NOD1, NLRP1 | FOLH1 2552/4885KDM6B 3715/4885LMNA 1234/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.